Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.

Suppression of ovarian tumor growth by chromosome 3p was demonstrated in a previous study. Deleted in Lung and Esophageal Cancer 1 (DLEC1) on 3p22.3 is a candidate tumor suppressor in lung, esophageal, and renal cancers. The potential involvement of DLEC1 in epithelial ovarian cancer remains unknown. In the present study, DLEC1 downregulation was found in ovarian cancer cell lines and primary ovarian tumors. Focus-expressed DLEC1 in two ovarian cancer cell lines resulted in 41% to 52% inhibition of colony formation. No chromosomal loss of chromosome 3p22.3 in any ovarian cancer cell line or tissue was found. Promoter hypermethylation of DLEC1 was detected in ovarian cancer cell lines with reduced DLEC1 transcripts, whereas methylation was not detected in normal ovarian epithelium and DLEC1-expressing ovarian cancer cell lines. Treatment with demethylating agent enhanced DLEC1 expression in 90% (9 of 10) of ovarian cancer cell lines. DLEC1 promoter methylation was examined in 13 high-grade ovarian tumor tissues with DLEC1 downregulation, in which 54% of the tumors showed DLEC1 methylation. In addition, 80% of ovarian cancer cell lines significantly upregulated DLEC1 transcripts after histone deacetylase inhibitor treatment. Therefore, our results suggested that DLEC1 suppressed the growth of ovarian cancer cells and that its downregulation was closely associated with promoter hypermethylation and histone hypoacetylation.

[1]  N. Kawamata,et al.  Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis , 2004, Cancer.

[2]  W. Wong,et al.  Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. , 2004, Cancer genetics and cytogenetics.

[3]  Paul Cairns,et al.  Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients , 2004, Cancer Research.

[4]  J. Minna,et al.  Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas , 2004, Oncogene.

[5]  Yang Li,et al.  Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array , 2004, Human Genetics.

[6]  M. Toyota,et al.  Epigenetic Inactivation of TMS1/ASC in Ovarian Cancer , 2004, Clinical Cancer Research.

[7]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[8]  P. Bates,et al.  OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer , 2003, Nature Genetics.

[9]  M. Nachtigal,et al.  Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. , 2003, Molecular cancer research : MCR.

[10]  A. Protopopov,et al.  Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas , 2003, Oncogene.

[11]  Luc Girard,et al.  Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  J. Minna,et al.  Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers , 2002, Oncogene.

[13]  Tim Hui-Ming Huang,et al.  Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[15]  G. Pfeifer,et al.  Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas , 2001, International journal of cancer.

[16]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[17]  T. Godfrey,et al.  Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. , 2000, Cancer research.

[18]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[19]  A. Bird,et al.  Methylation-Induced Repression— Belts, Braces, and Chromatin , 1999, Cell.

[20]  C. Morelli,et al.  Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. , 1999, Cancer research.

[21]  Y. Nakamura,et al.  Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. , 1999, Cancer research.

[22]  G. Strathdee,et al.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.

[23]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[24]  A. Mes-Masson,et al.  Mapping of chromosome 3p deletions in human epithelial ovarian tumors , 1998, Oncogene.

[25]  R. Angioli,et al.  Hereditary and sporadic ovarian cancer: genetic testing and clinical implications (review). , 1998, International journal of oncology.

[26]  A. Marchetti,et al.  Evaluation of FHIT gene alterations in ovarian cancer. , 1998, British Journal of Cancer.

[27]  M. Skolnick,et al.  Genetic susceptibility to breast and ovarian cancer. , 1997, Pathologie-biologie.

[28]  R. Huddart,et al.  Molecular genetic analysis of the von Hippel-Lindau disease (VHL) tumour suppressor gene in gonadal tumours. , 1995, European journal of cancer.

[29]  R. Berkowitz,et al.  Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). , 1995, Experimental cell research.

[30]  C. Morelli,et al.  Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions on 3p involved in ovarian cancer. , 1994, Oncogene.

[31]  M. Friedlander,et al.  Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer , 1992, International Journal of Gynecologic Cancer.

[32]  Y. Nakamura,et al.  Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphisms. , 1992, Oncogene.

[33]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.